

Bladder Cancer Urothelial Carcinoma

**Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma**

**Trial Status**  
Completed

**Trial Runs In**  
36 Countries

**Trial Identifier**  
NCT02807636 2016-000250-35  
WO30070

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy versus chemotherapy alone in participants with untreated advanced urothelial cancer.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT02807636 2016-000250-35 WO30070**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥ 18 Years

**Healthy Volunteers**  
No

---